{"filings":[{"id":94144,"accession_number":"0001193125-26-205124","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences Q1 net loss $97.4M; cash $866.4M to fund into 2028; NDA for bezuclastinib in GIST under FDA review","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $97.4M for Q1 2026 vs $72.0M Q1 2025; R&D spend $75.4M, G&A $28.2M.","Cash, equivalents and marketable securities $866.4M as of March 31, 2026, expected to fund operations into 2028.","FDA has accepted NDA for bezuclastinib in NonAdvSM (PDUFA Dec 30, 2026); NDA for GIST submitted under RTOR with Breakthrough Therapy designation.","Pivotal Phase 3 PEAK trial data in GIST selected for oral presentation at 2026 ASCO annual meeting on May 30.","Inducement grants of options for 62,600 shares and 48,600 RSUs awarded to seven new employees on April 29, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106311,"accession_number":"0001193125-26-053131","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences reports Q4/FY2025 results; advances bezuclastinib NDAs in SM and GIST","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["SUMMIT NDA for bezuclastinib in NonAdvSM submitted Dec 2025; APEX NDA for AdvSM on track for 1H 2026.","PEAK NDA for bezuclastinib in 2L GIST initiated under RTOR and BTD; completion expected April 2026.","Cash, equivalents and marketable securities $900.8M as of Dec 31, 2025, sufficient into 2028.","Net loss $102.5M in Q4 2025, $328.9M full year, vs $67.9M and $255.9M in prior year periods.","Inducement grants: options to purchase 59,300 shares and 47,000 RSUs to 12 new employees."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122623,"accession_number":"0001193125-25-311217","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cogent reports positive SUMMIT and APEX trial results for bezuclastinib in mastocytosis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SUMMIT Part 2: mean TSS change -24.3 (-43%) vs placebo -15.4 (-29%), p<0.001; 34.3% vs 18.1% had >=50% TSS reduction (p=0.01).","SUMMIT: 87.4% had >=50% serum tryptase reduction; 75.6% had >=50% bone marrow mast cell reduction (p<0.001 vs placebo).","APEX Part 2 top-line: 57% ORR (CR+CRh+PR+CI) per mIWG criteria; 80% ORR per pure pathological response.","APEX: 89% had >=50% serum tryptase reduction; 91% had >=50% KIT D816V VAF reduction; no discontinuations due to TRAEs.","Cogent expects to submit NDA for bezuclastinib in AdvSM to FDA in H1 2026; detailed APEX data at scientific meeting H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122622,"accession_number":"0001193125-25-286158","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Cogent completes $230M 1.625% convertible senior notes offering due 2031","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Aggregate principal $230M including full exercise of $30M over-allotment option by underwriters.","Notes bear 1.625% interest payable semiannually on May 15 and Nov 15, starting May 15, 2026; mature Nov 15, 2031.","Initial conversion rate 22.2469 shares per $1,000 principal (conversion price ~$44.95); settlement in cash, stock, or combo at company's election.","Notes are senior unsecured obligations; redeemable at company's option after Nov 20, 2029 subject to stock price conditions.","Noteholders may require repurchase upon a Fundamental Change (e.g., business combination, delisting) at principal plus accrued interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122621,"accession_number":"0001193125-25-278679","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Cogent Biosciences prices 9.7M share offering at $31 and $230M 1.625% convertible notes due 2031 for ~$475M net","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Equity offering of 9,677,420 shares at $31.00 per share, upsized from $200M, with underwriters exercising over-allotment for additional 1,451,613 shares.","Convertible notes offering of $200M aggregate principal (upsized to $230M) of 1.625% senior notes due 2031, conversion premium ~45% above equity offering price.","Combined net proceeds expected ~$475.3M, to be used to repay $50M term loan and fund development/commercialization of bezuclastinib.","Offerings led by J.P. Morgan, Jefferies, Leerink Partners, and Guggenheim Securities for equity; Jefferies and J.P. Morgan for notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122620,"accession_number":"0001193125-25-273315","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cogent: bezuclastinib combo reduces progression risk by 50% in Phase 3 GIST trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PEAK trial met primary endpoint: HR 0.50 (95% CI: 0.39–0.65) for progression-free survival.","Median PFS 16.5 months (bezuclastinib + sunitinib) vs 9.2 months (sunitinib alone).","Objective response rate 46% (combo) vs 26% (sunitinib), safety generally manageable.","Company plans NDA submission for NonAdvSM by end 2025; GIST NDA in H1 2026.","Top-line APEX AdvSM trial results expected December 2025; ASH presentations upcoming."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122619,"accession_number":"0001193125-25-261797","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences reports Q3 net loss $80.9M; cash $390.9M; PEAK, APEX readouts in Nov/Dec 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and marketable securities at $390.9M; pro forma cash $430M expected to fund into 2027.","Net loss of $80.9M (Q3 2025) vs $70.6M (Q3 2024); R&D expenses $69.0M.","Phase 3 PEAK (GIST) top-line results expected Nov 2025; APEX (AdvSM) in Dec 2025.","NDA filing for NonAdvSM on track for year-end 2025; Breakthrough Therapy Designation granted for bezuclastinib.","Raised $215.8M net from public offering and $39M from ATM since July 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139327,"accession_number":"0001193125-25-201353","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Cogent Biosciences signs 7yr10mo lease for new Waltham HQ at $32/sq ft","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Leases 31,518 sq ft at 180 Third Avenue, Waltham, MA as new corporate headquarters, replacing existing HQ.","Term of 7 years 10 months starting expected May 2026; initial rent $32/sq ft with $1/sq ft annual increases.","Rent abatement for first 5 months; security deposit of ~$336,000 via letter of credit.","One option to extend lease for an additional 5 years.","Landlord performing turnkey buildout; no material tenant improvement costs for Cogent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139326,"accession_number":"0000950170-25-102433","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent reports positive SUMMIT trial, Q2 net loss $73.5M; pro-forma cash $453M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["SUMMIT trial met primary endpoint: TSS improvement 8.91 points vs placebo (p=0.0002); 87.4% bezuclastinib patients had ≥50% tryptase reduction.","Upcoming milestones: PEAK and APEX top-line results in 2H 2025; NDA submission by end of 2025.","Q2 net loss $73.5M (vs $59.0M YoY); R&D $62.2M; G&A $13.4M; cash $237.8M at June 30, 2025.","Pro-forma cash $453M including $215.8M net from July upsized offering; $400M debt facility with SLR Capital.","Inducement grants to 6 new employees: 172,450 options at $9.00, 10-yr term, 4-yr vest."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139325,"accession_number":"0001193125-25-157390","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Bezuclastinib SUMMIT trial beats all primary/secondary endpoints; NDA submission by end 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SUMMIT trial met primary endpoint: mean TSS reduction of 24.3 vs 15.4 placebo (p=0.0002); 8.91-point placebo-adjusted improvement.","87.4% of bezuclastinib patients had ≥50% reduction in serum tryptase vs 0% placebo (p<0.0001).","NDA submission to FDA expected by end of 2025; plan to present full data at medical meeting.","Raised ~$230M gross via offering of 22.2M shares at $9 (plus underwriter option fully exercised).","Cash balance ~$237M as of June 30, 2025; access to up to $350M via debt facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139324,"accession_number":"0001193125-25-155811","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cogent reports positive top-line results from SUMMIT trial of bezuclastinib in non-advanced systemic mastocytosis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SUMMIT Part 2 met primary endpoint with highly significant mean TSS reduction of 24.3 points vs placebo 15.4 (p=0.0002) at 24 weeks.","87.4% of bezuclastinib patients had ≥50% reduction in serum tryptase vs 0% on placebo (p<0.0001).","All key secondary endpoints achieved statistical significance, including KIT D816V VAF and bone marrow MC aggregates reductions.","Company on track to submit NDA to FDA for bezuclastinib in NonAdvSM by end of 2025; detailed results planned for medical meeting.","Safety profile manageable: most TEAEs low grade, discontinuations due to ALT/AST elevations (5.9%) all resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156906,"accession_number":"0001193125-25-138813","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Cogent Biosciences secures up to $400M non-dilutive debt facility; $50M drawn at closing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$400M credit facility from SLR; first tranche of $50M funded on June 11, 2025.","Interest rate: 4.75% + greater of 1-month SOFR or 4.15%; matures June 1, 2030.","Future tranches tied to milestones: $25M after positive SUMMIT data, $75M after positive PEAK data.","$50M additional upon $85M net product revenue on trailing 6 months by June 30, 2027; $200M mutual.","Proceeds for working capital; monthly interest-only until June 1, 2028, with possible deferral to 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156905,"accession_number":"0001193125-25-135337","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.03","5.07","7.01","9.01"],"status":"ready","headline":"Cogent stockholders approve officer exculpation; annual meeting results filed","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Approved amendment to certificate of incorporation to exculpate officers: 86,181,373 for, 4,422,462 against.","Re-elected directors Karen Ferrante (68,418,781 for) and Matthew E. Ros (77,274,345 for).","Ratified PricewaterhouseCoopers as auditor with 101,115,649 votes for.","Advisory vote on executive compensation approved: 89,797,699 for, 808,715 against.","Company presenting at Jefferies Global Healthcare Conference on June 5, 2025 (details in corporate presentation)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156904,"accession_number":"0000950170-25-063987","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences Q1 net loss $72M; cash $245.7M; SUMMIT readout in July","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $72.0M vs $58.3M YoY; R&D spend $63.0M (+20% YoY) driven by ongoing trials.","Cash & securities $245.7M, funded into late 2026; raised $24.3M via ATM in Q1.","Top-line SUMMIT results in non-AdvSM due July 2025; APEX AdvSM in H2, PEAK GIST by year-end.","Bezuclastinib OLE data showed 65% mean TSS improvement at 48 weeks; 88% achieved ≥50% reduction.","Early-stage pipeline (KRAS, PI3Kα, FGFR2/3, ErbB2) preclinical data presented at AACR."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175287,"accession_number":"0000950170-25-026103","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences Q4/FY2024 net loss $67.9M/$255.9M; SUMMIT results due July 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 $67.9M, FY $255.9M (vs $54.4M and $192.4M); R&D spend $62M/$232.7M.","Cash, equivalents and marketable securities $287.1M at 12/31/24 plus $25M from ATM; runway into late 2026.","Top-line SUMMIT (NonAdvSM) results expected July 2025; APEX (AdvSM) enrollment complete, data 2H 2025.","NDA submission for bezuclastinib planned by end-2025; PEAK (GIST) top-line by end-2025.","Preclinical IND for ErbB2 inhibitor CGT4255 and PI3Kα inhibitor CGT6297 planned in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192239,"accession_number":"0001193125-24-273393","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cogent Biosciences reports positive Phase 2 bezuclastinib data in AdvSM and NonAdvSM at ASH 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["APEX (AdvSM): 52% ORR per mIWG-MRT-ECNM; 61% in TKI-naïve; 83% at 100 mg BID. Median PFS not reached; 24-mo PFS rate 82%.","100% PPR ORR at 100 mg BID; 94% of patients had >=50% tryptase reduction; 93% had >=50% KIT D816V VAF reduction.","SUMMIT (NonAdvSM): 56% mean TSS improvement; 76% of patients had >50% MS2D2 reduction; 49% mean MC-QoL improvement at 24 wks.","95% of patients with baseline tryptase >=20 ng/mL achieved <20 ng/mL by week 24; 84% with baseline >11.4 ng/mL achieved <11.4.","SUMMIT Part 2 enrollment complete (179 patients); top-line expected July 2025. APEX Part 2 enrollment completion Q1 2025; top-line mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192238,"accession_number":"0000950170-24-124653","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Q3 net loss $70.6M; PEAK trial enrolls 413 patients, top-line data in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $70.6M in Q3 2024 vs $55.4M in Q3 2023; cash $345.5M sufficient into late 2026.","Phase 3 PEAK GIST trial completed enrollment (413 patients); IDMC recommended continuation after futility analysis.","Top-line results expected from SUMMIT (2H 2025), APEX (mid-2025), PEAK (end of 2025).","Phase 1 trial initiated for CGT-4859 FGFR2 inhibitor; preclinical data for KRAS and PI3K inhibitors presented.","Inducement grants of options to purchase 132,350 shares to three new employees."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208722,"accession_number":"0001193125-24-211584","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cogent Biosciences completes PEAK trial enrollment and advances past interim futility analysis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 PEAK trial enrolled 413 GIST patients, exceeding target; top-line results expected by end of 2025.","Independent Data Monitoring Committee recommended continuing PEAK study after pre-planned interim futility analysis.","SUMMIT trial in NonAdvSM now expects to complete enrollment in Q1 2025, three months earlier than projected.","Darara Dibabu appointed VP of Marketing; granted inducement award of 100,000 stock options at $10.74 per share.","Bezuclastinib combination with sunitinib for second-line GIST is primary focus of registration-directed trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208721,"accession_number":"0000950170-24-091220","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences Q2 2024 net loss $59.0M; cash $389.9M; trial enrollment on track for 2025 readouts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $389.9M as of June 30, 2024; expected to fund operations into 2027.","Net loss $59.0M for Q2 2024, compared to $44.1M in Q2 2023; R&D expenses $54.3M.","Enrollment in SUMMIT, PEAK, APEX registration-directed trials on track; topline results expected from all three in 2025.","Appointed Cole Pinnow as Chief Commercial Officer; initiated IND-enabling studies for CNS-penetrant ErbB2 program.","Plan to initiate Phase 1 trial for FGFR2 inhibitor in H2 2024; IND-enabling studies for PI3Ka program ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226457,"accession_number":"0001193125-24-169756","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cogent reaches FDA alignment on MS2D2 endpoint for SUMMIT trial; enrollment timeline reaffirmed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA alignment on novel patient-reported outcome measure MS2D2 for Part 2 of SUMMIT trial in NonAdvanced Systemic Mastocytosis (NonAdvSM).","SUMMIT Part 2 enrollment on track to complete Q2 2025; top-line results expected by end of 2025.","APEX study (Advanced SM) enrollment to complete end of 2024; top-line results mid-2025.","PEAK study (GIST) enrollment expected to complete Q3 2024; top-line results by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226456,"accession_number":"0001193125-24-155116","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Cogent Biosciences shareholders approve doubling authorized common stock to 300M shares","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Amendment increases authorized common shares from 150M to 300M; total authorized shares from 160M to 310M.","Outdated reverse stock split provisions deleted from the certificate of incorporation.","All three director nominees elected; Andrew Robbins received 67.8M for, Peter Harwin received 51.7M for.","Advisory vote on executive compensation passed with 69.6M for vs 6.7M against; future votes set for annual frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226455,"accession_number":"0000950170-24-053974","cik":1622229,"company_name":"Cogent Biosciences, Inc.","ticker":"COGT","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cogent Biosciences Q1 net loss $58.3M; cash $435.7M funds operations into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities $435.7M as of Mar 31, 2024, up from $273.2M year-end 2023.","Net loss $58.3M in Q1 2024 vs $38.6M in Q1 2023; R&D expenses $52.7M (up 46% YoY).","Enrollment on track in APEX, PEAK (end 2024) and SUMMIT (Q2 2025); topline results expected in 2025.","Completed oversubscribed private placement yielding $213.4M net proceeds.","Selected 100 mg once-daily dose for SUMMIT Part 2 based on 51% mean TSS improvement at week 12."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6069230930.795712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}